[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356822-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356822-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rbm15b-mediated-m6a-modification-of-foxm1-activates-the-aurkatpx2-axis-to-promote-epithelial-mesenchymal-transition-driven-endometrial-cancer-progression","RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression","","Endometrial cancer (EC) is rising worldwide, while its molecular drivers remain insufficiently defined. This study tests whether RBM15B-mediated m6A modification of FOXM1 promotes EC progression via the AURKA/TPX2 axis and epithelial-mesenchymal transition (EMT). Bioinformatics evaluated FOXM1 expression and patient prognosis, and biochemical assays assessed m6A regulation, RNA stability, and FOXM1 activity. Functional experiments measured proliferation, migration, invasion, and stemness. RBM15B increased m6A on FOXM1 mRNA, stabilizing FOXM1 and activating AURKA/TPX2 to enhance EMT and malignant phenotypes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rbm15b-mediated-m6a-modification-of-foxm1-activates-the-aurkatpx2-axis-to-promote-epithelial-mesenchymal-transition-driven-endometrial-cancer-progression/356822/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rbm15b-mediated-m6a-modification-of-foxm1-activates-the-aurkatpx2-axis-to-promote-epithelial-mesenchymal-transition-driven-endometrial-cancer-progression/356822.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central hypothesis of this study?","Question",{"text":63,"@type":64},"RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote EC progression through EMT.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which key molecular relationship does the study establish?",{"text":68,"@type":64},"RBM15B increases m6A modification on FOXM1 mRNA, stabilizing FOXM1 and promoting downstream AURKA/TPX2 signaling.",{"name":70,"@type":61,"acceptedAnswer":71},"How does FOXM1 affect endometrial cancer cell behavior in this work?",{"text":72,"@type":64},"FOXM1 enhances EC cell proliferation, migration, invasion, and stemness, aligning with stronger malignant phenotypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356822,1790842163,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","CELL ADHESION & MIGRATION  \n2026, VOL. 20, NO. 1, 2674357 [https://doi.org/10.1080/19336918.2026.2674357](https://doi.org/10.1080/19336918.2026.2674357)  \nRBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial  \ncancer progression  \nLijing Zhang and Ping Wu  \nDepartment of Gynaecology, Yiwu Central Hospital, Yiwu, Zhejiang, China  \nABSTRACT  \nEndometrial cancer(EC) is increasing worldwide, but its molecular mechanisms remain unclear. This study explored whether RBM15B-mediated m6A modification of FOXM1 promotes EC progression through the AURKA/TPX2 axis and epithelial-mesenchymal transition(EMT) . Bioinformatics analyses assessed FOXM1 expression and prognosis in EC. RNA pull-down, MeRIP-PCR, dot blot, and RNA stability assays examined m6A regulation. Colony formation, Transwell, wound healing, and tumor sphere assays evaluated malignant behaviors. FOXM1 was significantly upregulated in EC and associated with unfavorable prognosis. Functional assays showed that FOXM1 enhanced proliferation, migration, invasion, and stemness of EC cells. Mechanistically, RBM15B increased m6A modification of FOXM1 mRNA and promoted expression. RBM15B knockdown inhibited malignant phenotypes and reduced activation of the downstream AURKA/ TPX2 pathway. RBM15B-mediated m6A methylation stabilizes FOXM1 expression, activates the AURKA/TPX2 axis, and promotes EMT and EC progression. Targeting the RBM15B/FOXM1/AURKA/TPX2 pathway may offer therapeutic potential.  \nARTICLE HISTORY  \nReceived 24 October 2025 Revised 23 April 2026 Accepted 11 May 2026  \nKEYWORDS  \nEndometrial cancer; epithelial-mesenchymal transition; FOXM1; N6-methyladenosine  \nIntroduction  \nEndometrial cancer (EC) is one of the most prevalent malignancies of the female reproductive system, with a higher incidence in peri-menopausal and post-menopausal women [ 1] . However, recent trends indicate a shift toward younger age groups, largely attributed to risk factors such as obesity, hypertension, diabetes, and other underlying conditions [2]. By 2040, EC is projected to become the third most common cancer in women and the fourth leading cause of cancer-related mortality [3] . While early-stage EC patients often experience favorable outcomes with surgical and adjuvant treatments, prognosis dramatically worsens upon metastasis, significantly reducing survival rates [4] . Moreover, treatment options for metastatic EC are limited and frequently associated with recurrence, posing a substantial threat to women’s health. As such, a comprehensive understanding of the molecular mechanisms underlying EC metastasis is essential for improving patient outcomes and developing novel therapeutic strategies.  \nForkhead box M1 (FOXM1) is a critical transcription factor that plays a pivotal role in regulating various biological processes, including cell cycle control, DNA repair, apoptosis, and cell proliferation [5] . Recent research has highlighted the essential role of FOXM1 in the initiation and progression of multiple cancers [5,6]. Overexpression of FOXM1 has been closely linked to increased tumor cell proliferation, invasiveness, metastasis, and drug resistance, making it a central focus of cancer research [7] . This transcription factor drives tumorigenesis by regulating genes associated with the cell cycle, thereby promoting tumor cell growth and enhancing resistance to therapy. For instance, FOXM1 has been shown to upregulate the cell cyclerelated gene CDKN1C, thereby facilitating the proliferation of bladder cancer cells [8] . Moreover, studies have demonstrated that FOXM1 is abnormally overexpressed in EC and is strongly correlated with poor patient prognosis [9], which has drawn significant attention. Notably, emerging evidence indicates that the expression of FOXM1 is regulated by m6A methylation, a pivotal post-transcriptional modification. For example, Jiang et al. revealed that HNRNPA2B1-mediated m6A modificat","cbCairWeHur9ai8T","https://ap.wps.com/l/cbCairWeHur9ai8T","pdf",5850398,17,"English","# Introduction\n## FOXM1 in endometrial cancer and EMT\n# Methods and experimental assays\n## Bioinformatics and expression/prognosis analysis\n## m6A regulation and RNA stability assays\n## Cellular functional assays","[{\"question\":\"What is the central hypothesis of this study?\",\"answer\":\"RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote EC progression through EMT.\"},{\"question\":\"Which key molecular relationship does the study establish?\",\"answer\":\"RBM15B increases m6A modification on FOXM1 mRNA, stabilizing FOXM1 and promoting downstream AURKA/TPX2 signaling.\"},{\"question\":\"How does FOXM1 affect endometrial cancer cell behavior in this work?\",\"answer\":\"FOXM1 enhances EC cell proliferation, migration, invasion, and stemness, aligning with stronger malignant phenotypes.\"}]","RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression | PDF",1790127490,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78a6ef79349a5761ef2d39ba73f2f0b8.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1728cd0c5c029ccf64ce17014fb24fee.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6430b3958e35ce7e496e3ec840c3a5f1.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/738902b0156114e8dc23340f338a3542.webp",980,1306]